Ensysce Biosciences, Inc. financial data

Symbol
ENSC on Nasdaq, ENSCW on OTC
Location
La Jolla, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 204% % 0.08%
Debt-to-equity 79% % 4.6%
Operating Margin -246% % -72%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,541,262 shares -82%
Common Stock, Shares, Outstanding 3,181,074 shares -77%
Entity Public Float $4,000,000 USD -13%
Common Stock, Value, Issued $320 USD -77%
Weighted Average Number of Shares Outstanding, Basic 2,886,059 shares 338%
Weighted Average Number of Shares Outstanding, Diluted 2,886,059 shares 338%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $4,487,973 USD 1.5%
Research and Development Expense $10,566,497 USD 87%
General and Administrative Expense $4,957,072 USD -2.4%
Operating Income (Loss) $11,035,596 USD -75%
Nonoperating Income (Expense) $62,956 USD -30%
Earnings Per Share, Basic -4 USD/shares 94%
Earnings Per Share, Diluted -4 USD/shares 94%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,673,218 USD -60%
Other Assets, Current $68,134 USD 279%
Assets, Current $2,928,270 USD -68%
Property, Plant and Equipment, Net $123,643 USD
Other Assets, Noncurrent $127,551 USD -57%
Assets $3,179,464 USD -66%
Accounts Payable, Current $463,458 USD -76%
Liabilities, Current $2,304,715 USD -18%
Other Liabilities, Noncurrent $1,033 USD
Liabilities $2,304,750 USD -18%
Retained Earnings (Accumulated Deficit) $136,952,351 USD -8.7%
Stockholders' Equity Attributable to Parent $1,203,363 USD -83%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $874,714 USD -87%
Liabilities and Equity $3,179,464 USD -66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,707,412 USD 50%
Net Cash Provided by (Used in) Financing Activities $1,257,826 USD -78%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 3,181,080 shares -77%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $449,586 USD -120%
Deferred Tax Assets, Valuation Allowance $40,361,645 USD 5%
Deferred Tax Assets, Gross $40,361,645 USD 5%
Depreciation $0 USD
Deferred Tax Assets, Operating Loss Carryforwards $29,728,009 USD 4.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1,500,000 shares 0%
Unrecognized Tax Benefits $1,826,993 USD 8.4%
Operating Lease, Payments $20,681 USD -9%
Additional Paid in Capital $138,155,394 USD 4%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense $1,248,065 USD 83271%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%